Jonathan David Schwartz - 11 Feb 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical & Gene Therapy Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan Schwartz
Issuer symbol
RCKT
Transactions as of
11 Feb 2025
Net transactions value
$0
Form type
4
Filing time
13 Feb 2025, 16:01:34 UTC
Previous filing
27 Feb 2025
Next filing
20 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +80,318 +47% $0.000000 252,731 11 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +119,682 $0.000000 119,682 11 Feb 2025 Common Stock 119,682 $9.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 This option represents a right to purchase a total of 119,682 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Remarks:

Chief Medical & Gene Therapy Officer